FOP Now Has Three Approved Drugs for About 300 US Patients, Two of Them in 37 Days
Three drugs now divide an ultra-rare disease by mechanism, route and age, and the newest competes on convenience and safety.
Athithi Verma
AbbVie Largely Dropped Its Constitutional Case but Still Says Botox Is Plasma-Derived and Exempt
Constitutional challenges to Medicare negotiation have failed repeatedly. AbbVie is now betting on the definition of its product.
Europe Approved Leriglitazone for Boys With cALD Two Years After the EMA Recommended Refusal
A drug the EMA refused two years ago is now approved, on a narrow label and under exceptional circumstances, with Europe first.
OrphanPulse Wk 39: A 900-Patient Disease Now Has Two Approved Drugs
Mirum licensed Atebrioz five months before its PDUFA date. The approval arrived a day early on a single Phase 2 cohort.
NeuroPulse Wk 39: Otsuka Opened Early Access the Day Before FUS-ALS Read Out
Otsuka opened early access for ulefnersen the day before the topline. A sponsor that prepares supply first expected to win.
DealPulse Signal Wk 39: Telix Paid in Stock and the Platforms Paid in Promises
Telix’s cheque was 61% of every upfront dollar disclosed this week. The platforms paid about 3% of their headline value.
Genentech Bets $1.5B+ on Earendil’s Bispecifics With $55M Upfront
The one clean upfront among this week’s discovery deals, and Earendil keeps more of the early clinical risk than most.
Lilly, InnoCare Strike $3.35B Pact, Heavy on Milestones, Light on Upfront
QuickDeal read/Deals Lilly, InnoCare Strike $3.35B Pact, Heavy on Milestones, Light on Upfront Athithi Verma· 24 September 2026· 2 min read· Synopulse InnoCare Pharma, listed in Hong Kong and Shanghai, said on 24 September 2026 that it has signed a strategic research collaboration and licence agreement with Eli Lilly. InnoCare will use its discovery platform … Read more
J&J Is Using Two Tecvayli Trials to Own Myeloma’s First Relapse Whether or Not Patients Had Darzalex
J&J’s frontline success with Darzalex is manufacturing the monotherapy market for Tecvayli at first myeloma relapse.
Henlius Licensed a US pH-Switch Platform for Two T-Cell Engager Targets Without Disclosing Any Payment
Henlius bought a switch, not a molecule, and the deal discloses no dollar figure at all, not even a headline total.